Skip to main content
. 2007 May 15;104(21):9001–9006. doi: 10.1073/pnas.0703056104

Table 2.

mtDNA mutations in nononcocytic samples

Sample Diagnosis Base change Amino acid change Gene Het., % PSIC Database
BRCA3 BRduct T12601C F89L ND5 2.086 Novel
BRCA9 BRduct A13973T Q546L ND5 1.551 HmtDB
BRCA10 BRlob T9903C F233L COXIII 2.458 HmtDB
BRCA5 BRduct T9119C L198P ATP6 + 2.429 Novel
G5 AST T4016G L237R ND1 + 2.151 Novel
G15 AST T11204C F149L ND4 1.513 HmtDB
TC6 FA A12961G S209G ND5 1.521 HmtDB
TC7 HTN T11204C F149L ND4 1.513 HmtDB
TC12 PTC T11736C L326P ND4 2.552 Novel
TC19 PTC 10116delAT 31X ND3 Novel
TC8 FTC G3842A W179X ND1 38 Novel
TC18 PTC C7441A S513Y COXI 1.626 Novel
TC16 PTC A8725G T67A ATP6 1.537 Novel
TC4 HTN G8572A G16S ATP6 1.983 HmtDB

Het., heteroplasmy (% of mutated); AST, astrocytoma; BRduct, invasive ductal carcinoma of the breast; BRlob, invasive lobular carcinoma of the breast; FA, follicular thyroid adenoma; FTC, follicular thyroid carcinoma; HTN, hyperplastic thyroid module; PTC, papillary thyroid carcinoma. Bold indicates disruptive mutations.